Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Find the latest information on COVID-19, monkeypox, and the flu vaccine
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
PHASE 1/2 STUDY OF NOVEL HER2-TARGETING, TLR7/8 IMMUNE-STIMULATING ANTIBODY CONJUGATE (ISAC) BDC-1001 WITH OR WITHOUT IMMUNE CHECKPOINT INHIBITOR IN PATIENTS WITH ADVANCED HER2-EXPRESSING SOLID TUMORS
Sharma, M., Dumbrava, E., Carvajal, R., Catenacci, D., Emens, L., Hanna, G., Juric, D., Kang, Y., Lee, J., Lee, K., Li, B., Moore, K., Pegram, M., Pohlmann, P., Rasco, D., Spira, A., Tan, A., Wang, D., Ackerman, S., LeBlanc, H., Dornan, D., Kowanetz, M., Alonso, M., Perez, E., Perez, E.
BMJ PUBLISHING GROUP. 2020: A244
View details for DOI 10.1136/jitc-2020-SITC2020.0401
View details for Web of Science ID 000616665300390